OCULIS ANNOUNCES AN OVERSUBSCRIBED US$57 MILLION SERIES C FINANCING
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01
Category: Supramolecular systems
Oculis aces the Phase 2 clinical trial for OCS-01 treating DME
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME
Asymmetric synthesis with cinchona-decorated CD in a continuous-flow membrane reactor
Over the last two decades organocatalysis has become an attractive synthetic tool in asymmetric catalysis. However, the increasing demand for
Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications
Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications, Volume One: Types and Triggers discusses, in detail, the recent trends in
Novel polyrotaxane for Niemann Pick disease type C treatment
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
Cyclodextrins as theranostics
The application of cyclodextrins as excipients is wellspread, common knowledge worldwide. Their application as APIs is getting huge publicity, developments
Host–guest interaction using a coordination polymer gel
Mimicking the host–guest (e.g. enzyme–substrate) interaction in the nature of a temperature-controlled stepwise release and capture of cyclodextrin was achieved
Nanoaggregation on command
ScienceDaily reported on the effect of cyclodextrins as parts of synthetic receptors on the aggregation of proteins, recently published by